Title of Invention

METHOD FOR PRODUCING OPTICALLY ACTIVE 2-METHYL-ALKANOLS

Abstract

The invention relates to a method for producing optically active 2-methylalkane-1-ol of general formula (III), comprising the following steps: (i) carbonyl-selective reduction of 2-methylalk-2-en-1-al of general formula (I) to 2-methylalk-2-en-1-ol of general formula (II), (ii) enantioselective hydration of 2-methylalk-2-en-1-ol to give the compound of general formula (III), (iii) increasing the optical yield of the optically active 2-methylalkane-1-ol (III) obtained in step (ii) by way of a lipase-catalyzed acylation reaction, whereby R represents C1-C10 alkyl.

Full Text

Method for producing optically active 2-methyl-alkanols Description The present invention relates to a novel process for preparing optically active 2-methylalkan-1-ol starting from 2-alkylpent-2-enal. Prior art The preparation of optically active 2-methylpentan-1-ol ("methylpentanol") by various processes has previously been described in the literature. Thus, for example, M. A. Jermyn et al. (Aust J. Chem. 1967, 20, 2283-2284) obtain R-methylpentanol by hydrolyzing the p-toluenesulfonate of L-valine (R)-2-methylpentyl ester. Oppolzer et al. (Helv. Chim. Acta 1985, 68, 212-215) obtain R-methylpentanol by diastereoselective ester enolate alkylation of a chiral sultam. Danishefsky et al. (J. Org. Chem. 1986, 51, 5032-5036) obtain R-2-methylpentanol by diastereoselective imide enolate alkylation of a chiral oxazolidinone. Effenberger et al. {Tetrahedron: Asymmetry 1993, 4, 823-833) obtain R-methylpentanol from racemic methylpentanol by lipase-catalyzed enantioselective acylation. The processes described above produce optically active methylpentanol in an economically unsatisfactory way because of costly starting materials, multistage synthesis, insufficient yields or very elaborate purification. Statement of object It is therefore an object of the present invention to provide a process for preparing optically active 2-methylalkan-1-ol that avoids, completely or at least partly, the disadvantages described above. Description of the invention We have found that this object is achieved by a process for preparing optically active 2-methyialkan-1-ol of the general formula (III) comprising the following steps; (i) carbonyl-selective reduction of 2-methylalk-2-en-1 -ai of the general formula (I) to 2-methylaik-2-en-1-oi of the general formula (II), (ii) enantioselective hydrogenation of 2-methyIalk-2-en-1-ol to the general formula (iii), (iii) increasing the optical yield of the optically active 2- methylalkan-1-ol (III) obtained in step (ii) by a lipase-catalyzed acylation reaction, Only one enantiomer (III) is drawn in the formula scheme shown above. However, it is pointed out that the process of the invention also includes the preparation of the respective other enantiomer (III) - which is not drawn herein. The enantiomer (III) which is desired in each case can be obtained through selecting the appropriate catalyst system in step (ii). In the formula images (I) to (III) shown above, the radical R means CrCi0-alkyl, where the alkyl radical may be straight-chain or branched, in particular methyl, ethyl, n-propyl and isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl. This definition also comprises in addition substituted alkyls in which one or more, preferably one to three, hydrogen atoms are replaced by radicals such as F, CI, Br, I, N02, NH2, NH(alkyl), N(alkyl)2, OH, SH, CN. The individual steps of the process are described below: Step (i): carbonyl-selective reduction The carbonyl-selective reduction of 2-methylalk-2-en-1-al to 2-methylalk-2-en-1~ ol can be carried out by various processes known to the skilled worker. Examples of such processes comprise hydride-transferring reagents or catalysts such as, for example, main group element hydrides or transition metal complexes which can act as catalysts, transfer hydrogenations, reductions with metals or low valency metal salts, diimine reductions or hydrogenations. A compilation of such processes is described for example in R. L. Larock, Comprehensive Organic Transformations, Wiley-VCH, New York, 1999. Depending on the selectivity of the catalyst system used in step (i) and on the chosen conditions, small amounts of the over-hydrogenated product (III) may be produced as racemate in step (i). Since this racemate (III) could impair the optical yield of the enantioselective double-bond hydrogenation provided in step (ii), it is advisable, following step (i), if appropriate to carry out a purification of the 2-methylalk-2-en-1-ol (II) produced, in order to remove any unreacted starting material (I) or over-hydrogenated racemic (III). Such a purification can preferably take place by distillation, and it may be appropriate in particular for increasing the yield to add a higher-boiling component to the reaction mixture to be separated. Step (ii): enantioselective hydrogenation The enantioselective hydrogenation of 2-methylalk-2-en-1-ol to optically active 2-methylalkan-1-ol can be carried out using transition metal complex catalysts, in particular those with transition metals of groups 8-11. Transition metal complex catalysts can be formed from a metal-containing precatalyst and a ligand. Complexes comprising Ru, Rh, Ir, Pd, Pt are preferred as precaiaiyst, and complexes comprising Ru and Rh are particularly preferred as precatalyst. Such preferred precatalysts are metal complexes for example RhCI3, Rh(OAc)3, [Rh(cod)CI]2l Rh(CO)2acac, [Rh(cod)OH]2, [Rh(cod)OMe]2, Rh4(CO)12, Rh6(CO)16and RuCI3, Ru(acac)3, [Ru(benzene)CI]2, [Ru(cymene)l2], Ru(methallyl)2(cod). The transition metal compounds and complexes mentioned, and further suitable ones, are known and described in the literature or can be prepared by the skilled worker in analogy to the compounds already known. Ligands are P, As, Sb-containing compounds as well as compounds which are linked via a carbon atom to the transition metal catalyst complex fragment. Chiral P-containing ligands are particularly preferred. Particularly preferred ligands are phosphorus-containing compounds with the ability to develop atropisomerism in relation to two aryl or hetaryl systems as depicted below: R1, R2 (identical or different): subst. or unsubst. aryl, heteroaryl, alkyl, cycloalkyl, where the subst. may be H, halogen, alkyi, alkoxy R3, R4 (identical or different): subst. or unsubst. aryl, heteroaryl, alkyl, cycloalkyl, where the subst. may be H, halogen, alkyl, alkoxy R5, R5\ R6, R6' (identical or different): with R = H, halogen, alkyl, aryl, alkoxy, amino, thio R7, R7' (identical or different): with R = H, halogen, alkyl, aryl, alkoxy, amino, thio Preparation of the abovementioned transition metal complex catalysts from precatalyst and ligand is known and described in the literature, e.g. H.U. Blaser, B. Pugin, F. Spindler in "Applied homogeneous and heterogeneous catalysis with organometallic compounds", Ed. B. Cornils, W.A. Herrmann, p. 992 ff. VCH Weinehim , 1996, ISBN, 3-527-29286-1. The reaction temperature for the enantioselective hydrogenation can be between -10°C and 150°C, preferably between 0-120°C, particularly preferably between 10-100°C. The reaction pressure for the enantioselective hydrogenation can be between 0.1 to 600 bar, preferably between 50 and 250 bar. The catalyst used for step (ii) is normally employed in a catsubstrate ratio of The reaction time normally depends on the reaction temperature and on the pressure conditions prevailing during the reaction and the amounts of catalyst used; it is normally between 1 and 50 hours, preferably 5 to 25 hours. The following solvents can preferably be used: methanol, ethanol, i-propanol, propanol, butanol, sec-butanol, tert-butanol, CH2CI2, CHCI3, dichloroethane, EtOAc, THF, TBME, Et20, Bu20, toluene, xylene, benzene, alkanes of the general formula CnH2n+2 with n = 5-15 and mixtures thereof. Methanol, ethanol, propanol, i-propanol are particularly preferred. Step (iii): Increasing the optical yield of the optically active 2-methylalkan-1-ol (III) obtained in step (ii) by a lipase-catalyzed acylation reaction. Step (iii) serves to improve even further the ratio obtained in step (ii) of the optical isomers of the 2-methyIalkan-1-ol (III). For this purpose, the mixture obtained in step (ii) is reacted (acylated) with an acylating agent under the catalytic action of a lipase, with the lipase selectively acylating one enantiomer (III) and leaving the other enantiomer (III) unchanged. The lipase preferably acylates the enantiomer (III) which was not formed in enantiomeric excess in step (ii) and thus leaves the product (III) formed in enantiomeric excess in step (ii) unchanged by lipase. The fact that the enantiomer not formed in excess in step (ii) is completely reacted by acylation leads to an increase in the optical purity - defined as enantiomeric excess - of the enantiomer (III) formed in enantiomeric excess in step (ii). The acylation product of (III) can be removed from the nonacylated enantiomer (III) by conventional processes such as chromatography, distillation or extraction. The lipases employed in step (iii) may be derived from a large number of organisms, for example mammals (pig), but especially from microorganisms. Preferred lipases are those derived from the species Pseudomonas or Burkholderia or have been modified, starting therefrom, by genetic manipulation processes, particularly preferably from Burkholderia plantarii or Pseudomonas fluorescens. The following lipases are particularly preferably used in step (iii): PFL Fluka (from Pseudomonal fluorescens), Novo 435 (Novozymes), Amano PS-C1, Amano PS-C2 and Amano PS-D1 (from Burkholderia cepacia, CAS No. 9001-62-1). The lipases can be employed in dissolved form or else in carrier-bound form. A carrier-bound lipase is preferably used. Acylating agents which can be employed for step (iii) are a large number of carboxyl derivatives which selectively acrylate the substrate (III) under lipase catalysis. Preferred acylating agents are acid anhydrides and alkenyl esters. Cyclic acid anhydrides such as succinic anhydride or vinyl esters are particularly preferred. Step (iii) can be carried out with or without additional solvent. If a solvent is to be employed, the following solvents are preferred: CH3CN, DMSO, NMP, CH2CI2, CHCI3, dichloroethane, EtOAc, THF, TBME, Et20, Bu20, 1,4-dioxane, acetone, 2-butanone, toluene, xylene, benzene, alkanes of the general formula CnH2n+2 with n = 5-15 and mixtures thereof. The preferred temperature for this step is between 0-60cC, particularly preferably between 5-35°C. The reaction time may be, depending on the chosen conditions, between one hour and several days. Normally, the progress of the reaction in step (iii) is followed, and the reaction is stopped when the desired enantiomeric excess is reached. The acylation product formed from one enantiomer (III) is then separated from the other, unreacted enantiomer (III). If an acid anhydride has been employed as acylating agent, the removal of the acylated product can preferably take place by extraction with aqueous base solution. The process of the invention can be carried out either discontinuously or continuously in all steps; however, it is also possible to carry out individual steps such as, for example, step (ii) continuously, and the other steps discontinuously. 595 mmol (58.4 g) of 2-methylpent-2-enal in 250 ml of diethyl ether are added dropwise to a suspension of 745 mmol (28.28 g) of lithium aluminum hydride in 550 ml of diethyl ether at -78°C. The mixture is stirred at 0°C for 30 min and at room temperature for 1.5 h and again cooled to 0°C, and 50 ml of water are added dropwise over the course of 40 min. After the addition is complete, 30 ml of a 13% strength sodium hydroxide solution and then a further 25 ml of water are added dropwise. The resulting colorless suspension is filtered through Celite filter gel, dried over MgS04 and concentrated in a rotary evaporator under atmospheric pressure. The crude product is distilled at 52CC and 11 mbar. 467 mmol (46.8 g, 79% yield) of 2-methylpent-2-en-1-ol are obtained. GC: detector: FID; separating column: 25m * 0.32mm OV-1 (Macherey & Nagel); film thickness = 0.5//m; temperature programme: 50°C, 2\ 20°C/\ 300°C: RT = 7.99 min 2-methylpent-2-en-1-ol. Example 2: Preparation of 2-methylpent-2-en-1-ol using Ru/Fe/C cat. A mixture of 349 mmol (35.0 g) of 2-methylpent-2-en-1-al, 17 ml of MeOH, 1.5 g of NMe3 and 0.35 g of BV 191 pass, is stirred at 60°C under a pressure of 40 bar of hydrogen for 22 h. Cooling to room temperature and filtration result in a crude product with the following composition (GC area %; without MeOH and NMe3): GC: detector: FID; separating column 30m x 0.32mm Optima wax (Macherey & Nagel); film thickness = 0.5 //m; temperature programme: 50°C, 2\ 20°C/\ 150°C, 15\20°C/\ 300°C; Example 3: Hydrogenation of 2-methylpent-2-en-1-ol with Ru/Josiphos system 13 //mol (7.7 mg) of Josiphos and 26 //mol (2.5 mg) of methanesulfonic acid are successively added to a suspension of 13//mol (4.2 mg) of Ru(COD)(methallyl)2 in 10 ml of MeOH, and the mixture is stirred in a glove box at room temperature for 30 min. The resulting solution is added to a solution of 65 mmoi (6.51 g) of 2-methyipent-2-en-1-ol in 30 ml of MeOH in an autoclave under protective gas. The mixture is stirred at 25°C under a pressure of 85 bar of hydrogen for 17 h. The crude product has the composition detailed below (GC area % without MeOH) and an ee of 58%. GC: detector: FID; separating column 30m x 0.32mm Optima wax (Macherey & Nagel); film thickness = 0.5/ym; temperature programme: 50°C, 2\ 2G°C/\ 150°C, 15', 20°C/\ 300°C; GC separation of R-, S- 2-methylpentanol (4 blank samples necessary): column switching with precolumn: 10m * 0.25mm Optimal (Macherey & Nagel) FD = 0.5 microm, and chiral column: 30m * 0.25mm BGB174 (BGB-Analytikvertrieb) FD = 0.25 microm; oven temp.: 60°C isothermal; precolumn: 0.3 bar He, chiral column: 1.1 bar He; column switching: RT = 2.9 to 3.5; valve 1 = On; RT = 2.9 min: increase in the precolumn pressure to 1.3 bar for 0.3 min: RT of R-2-methylpentanol = 1.9 min; RT of S-2-methylpentanol = 4.1 min. Example 4: Hydrogenation of 2-methylpent-2-en-1-ol using Ru/Solphos system 13/vmol (8.6 mg) of R-Solphos and 26/vmol (2.5 mg) of methane sulfonic acid are successively added to a suspension of 13 /ymol (4.2 mg) of Ru(COD)(methallyl)2 in 10 ml of MeOH, and the mixture is stirred in a glove box at room temperature for 30 min. The resulting solution is added to a solution of 260 mmol (26.04 g) of 2-methylpent-2-en-1 -ol in 120 ml of MeOH in an autoclave under protective gas. The autoclave is closed and, after injection of 280 bar of nitrogen, put in the intended location. It is stirred at 40°C under a pressure of 200 bar of hydrogen for 17 h. The crude product has the composition detailed below (GC area % without MeOH) and an ee of 74% Example 5: Lipase-catalyzed acylation 50 g (490 mmol) of R-2-methylpentanol with 66% ee were introduced into 500 ml of MTBE at RT, and 24.5 g (245 mmol) of succinic anhydride and 2.5 g of Amanolipase PS-D on clay were added and stirred at RT for 2 d. The progress of the reaction was followed by GC. As soon as the target ee is reached, the enzyme is filtered off and the filtrate is washed twice with 500 g of 10% sodium carbonate solution each time. The combined aqueous phases were then back-extracted once with 250 ml of MTBE; the combined organic phases were dried over MgS04 and freed of MTBE, and the residue was fractionally distilled. 14.5 g (35% of theory) of R-2-methylpentanol with 97% ee and > 98% chem. purity were obtained as a colorless oil. Example 6: Lipase-catalyzed acylation 50 g (490 mmol) of R-2-methylpentanol with 66% ee were introduced into 200 ml THF at RT, and 24.5 g (245 mmol) of succinic anhydride and 0.5 g of Amanolipase PS-D on clay were added and stirred at RT for 2 h. The progress of the reaction was followed by GC. As soon as the target ee is reached, the enzyme is filtered off and the filtrate is, after addition of 100 ml of MTBE, washed twice with 500 g of 10% sodium carbonate solution each time. The combined aqueous phases were then back-extracted once with 250 ml of MTBE; the combined organic phases were dried over MgS04 and freed of MTBE, and the residue was fractionally distilled. 25.1 g of R-2-methylpentanol with 97% ee and > 98% chem. purity were obtained as a colorless oil. We claim: 1. A process for preparing optically active 2-methylalkan-1-ol of the general formula (III) comprising the following steps: (i) carbonyl-selective reduction of 2-methylalk-2-en-1-al of the general formula (I) to 2-methylalk-2-en-1-ol of the general formula (II), (ii) enantioselective hydrogenation of 2-methylalk-2-en-1-ol to the general formula (iii), (iii) increasing the optical yield of the optically active 2- methylalkan-1-ol (III) obtained in step (ii) by a lipase-catalyzed acylation reaction, 2. The process according to claim 1, wherein R means methyl. 3. The process according to claim 1 and 2, wherein the reduction in step (i) is carried out using a complex main group element hydride. 4. The process according to claim 1 and 2, wherein the reduction in step (i) is carried out using a heterogeneous hydrogenation catalyst. 5. The process according to claim 1 and 2, wherein the hydrogenation in step (ii) is carried out using a transition metal complex catalyst. 6. The process according to claim 5, wherein Ru, Rh, Ir, Pd or Pt is used as transition metal. 7. The process according to claim 5, wherein a phosphorus-comprising chiral compound is employed as ligand of the transition metal complex. 8. The process according to claim 7, wherein a phosphorus-containing compound with the ability to develop atropisomerism in relation to two aryl or hetaryl systems are employed as ligand, according to the following structures where: R1, R2, which may be identical or different: may be subst. or unsubst. aryl, heteroaryl, alkyl, cycloalkyl, R3, R4, which may be identical or different: may be subst. or unsubst. aryl, heteroaryl, alkyl, cycloalkyl, R5, R5\ R6, R6\ which may be identical or different: may be H, halogen, alkyl, aryl, alkoxy, amino, thio, R7, R7\ which may be identical or different: may be H, halogen, alkyl, aryl, alkoxy, amino, thio, or: R5, R5', which may be identical or different: may be H, halogen, alkyl, aryl, alkoxy, amino, thio and R6 and R7, R6' and R7' form one or more rings which may comprise a further 1 or 2 double bonds and/or may comprise heteroatoms, R8, R8\ which may be identical or different: may be H, halogen, alkyl, aryl, alkoxy, amino, thio, X, X', which may be identical or different: may be S, O, NR9 R9 = H, alkyl, aryl, acyl, SO2R10 R10 = aryl, alkyl, fluoroalkyl, CF3 9. The process according to claim 7, wherein one of the following compounds are employed as ligand: (R)-2,2'-bis-diphenylphosphanyl- [1,1]binaphthalenyl; (S)-2,2'-bis-diphenylphosphanyl-[1,1']binaphthalenyl; (RJ-S^'-bis-diphenylphosphanyl^^^'^'-tetrahydro-[5,5']bi[benzo[1,4]dioxinyl]; (S)6,6'-bis-diphenylphosphanyl-2,3,2',3'-tetrahydro-^^bilbenzotl^dioxinyl]; (RJ-TJ^bis-diphenylphosphanyl-4,4,-dimethyl-3)4,3,,4l-tetrahydro-2HJ2,H-8,8,]bi[benzo[1,4]oxazinyl]; (S)-7,7,-bis-diphenylphosphanyl-4,4'-dimethyl-3,4,3,,4,-tetrahydro-2H,2,H-[S^bifbenzon ,4]oxazinyl]. 10. The process according to claim 1, wherein Amano lipase PS-D1 (CAS No. 9001-62-1), PS-C1 or PS-C2 is employed as lipase in step (iii). 11. The process according to claim 1, wherein succinic anhydride is used as acylating agent in step (iii). 12. The process according to claim 1, wherein THF, MTBE, diethyl ether, toluene or 1,4-dioxane is used as solvent in step (iii). 13. The process according to claim 1, wherein a distillation is carried out to purify the 2-methylalk-2-en-1-ol (II) obtained following step (i).

Documents:

1777-CHENP-2007 AMENDED PAGES OF SPECIFICATION 19-10-2012.pdf

1777-CHENP-2007 AMENDED CLAIMS 19-10-2012.pdf

1777-CHENP-2007 OTHER PATENT DOCUMENT 19-10-2012.pdf

1777-CHENP-2007 FORM-3 19-10-2012.pdf

1777-CHENP-2007 POWER OF ATTORNEY 19-10-2012.pdf

1777-CHENP-2007 CORRESPONDENCE OTHERS 01-02-2012.pdf

1777-CHENP-2007 CORRESPONDENCE OTHERS 04-11-2011.pdf

1777-CHENP-2007 EXAMINATION REPORT REPLY RECEIVED 19-10-2012.pdf

1777-chenp-2007-abstract.pdf

1777-chenp-2007-claims.pdf

1777-chenp-2007-correspondnece-others.pdf

1777-chenp-2007-description(complete).pdf

1777-chenp-2007-form 1.pdf

1777-chenp-2007-form 18.pdf

1777-chenp-2007-form 3.pdf

1777-chenp-2007-form 5.pdf